Mustang Bio Inc (NASDAQ:MBIO) – Research analysts at Oppenheimer issued their FY2017 earnings estimates for Mustang Bio in a research note issued on Wednesday. Oppenheimer analyst M. Breidenbach forecasts that the company will earn ($0.87) per share for the year. Oppenheimer currently has a “Outperform” rating and a $18.00 target price on the stock. Oppenheimer also issued estimates for Mustang Bio’s Q4 2017 earnings at ($0.24) EPS, Q1 2018 earnings at ($0.25) EPS, Q2 2018 earnings at ($0.27) EPS, Q3 2018 earnings at ($0.28) EPS, Q4 2018 earnings at ($0.32) EPS, FY2018 earnings at ($1.12) EPS, Q1 2019 earnings at ($0.32) EPS, Q2 2019 earnings at ($0.32) EPS, Q3 2019 earnings at ($0.30) EPS, FY2019 earnings at ($1.25) EPS, FY2020 earnings at ($1.36) EPS and FY2021 earnings at ($1.02) EPS.
Separately, CIBC initiated coverage on shares of Mustang Bio in a report on Thursday, December 21st. They issued an “outperform” rating and a $18.00 target price on the stock.
About Mustang Bio
Mustang Bio, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to utilize the power of the patient’s own immune system to eliminate cancer cells. It seeks to acquire rights to technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development and eventually either out-licensing or bringing the technologies to market.
Receive News & Ratings for Mustang Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mustang Bio and related companies with MarketBeat.com's FREE daily email newsletter.